Camp4 Therapeutics Corp. (CAMP) intrinsic value & 10-year financials
Camp4 Therapeutics Corp. (CAMP) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 4 fiscal years revenue grew 216.1% a year to $3.5M, with an average return on invested capital of 98.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.17
- Market cap
- $96.3M
- Revenue (FY2025)
- $3.5M
- Revenue growth (4-yr CAGR)
- 216.1%
- ROIC (10-yr avg)
- 98.2%
- Free cash flow (FY2025)
- -$29.8M
CAMP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $3.5M | -$80.4M | -$2.65 | -$29.8M | -1502.4% | 189.5% |
| FY2024 | $652.0K | -$51.8M | -$11.04 | -$46.0M | -8142.3% | 71.4% |
| FY2023 | $350.0K | -$49.3M | -$10.40 | -$44.8M | -14822.6% | 33.8% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Camp4 Therapeutics Corp revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Camp4 Therapeutics Corp has earned high returns on invested capital, averaging 35.7% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Camp4 Therapeutics Corp capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Camp4 Therapeutics Corp is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-88.02 per share.